# Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B

> **NCT02283671** · PHASE1 · COMPLETED · sponsor: **Sara Varea** · enrollment: 20 (actual)

## Conditions studied

- Multiple Sclerosis
- Neuromyelitis Optica

## Interventions

- **BIOLOGICAL:** Tolerogenic Dendritic cells loaded with myelin peptides

## Key facts

- **NCT ID:** NCT02283671
- **Lead sponsor:** Sara Varea
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09
- **Primary completion:** 2019-07-10
- **Final completion:** 2019-07-10
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2020-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283671, "Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02283671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*